Did you know?
ChinaBio® LLC is a consulting and advisory firm that helps Western companies come to China. We assist our clients with China strategy development, market research and analysis, partner/technology searches, competitive surveys, and market entry planning.

>> Learn more…
Site Search

>> Advanced Search

  Quick Search:
 
 

Free Newsletter

  Email address:
   

Lotus Reports Higher Q1 and New Asthma Drug

publication date: May 22, 2008
View a Printer Friendly version of this page, allowing you to print the page. Send a summary of this page to someone via email.

Lotus Pharmaceuticals, Inc. announced a 41% increase in revenues in Q1, though net income was up by a smaller 19%. The company booked $11.7 million in sales, while its profits totaled $1 million or 2 cents per share, fully diluted. Earlier this week, Lotus announced it will pay 48 million RMB ($7 million) to buy the patent and production rights to an asthma medicine, Laevo- Bambutero. More details...

Stock Symbol: (OTCBB: LTUS)




Sorry... this feature or article is only available to subscribers.

>> Learn more about our subscription plans...

>> Free email newsletter...

>> Login...

Login

  

    
   
Partner Events

China Medical Affairs Summit
June 12-13, 2014
Shanghai, China


>>More events...
Our Partners
Annual Sponsors
 
Official Partners
 
Supporting Partners
 
Media Partners